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ABSTRACT:
 
Using chromosome banding and fluorescence in situ hybridization (FISH) with painting
probes, sequential cytogenetic analysis was performed of two novel prostate cell lines, PZ-HPV-7 and
CA-HPV-10, established by human papillomavirus (HPV) 18 DNA transformation. PZ-HPV-7 originates
from a normal diploid prostate epithelial cell strain. PZ-HPV-7 progressed from an initial diploid to a
hypertetraploid chromosome number with a relative gain of chromosomes 5 and 20 (7 to 8 copies each).
Structural changes were limited; 3p
 
2
 
 (2 copies ), 3q
 
2
 
 (1 copy), and possibly a der(16p;12q). CA-HPV-10
originates from an epithelial cell strain derived from a high-grade human prostate cancer specimen,
which showed several karyotypic abnormalities including an extra Y chromosome and double minutes
(dmin). In early passage the karyotype of CA-HPV-10 appeared unstable with a decreasing number of
cells exhibiting dmin. In late passage the dmin were replaced by a large homogeneously staining region
(hsr) on 9p
 
+
 
 marker. The hsr was shown by FISH to be of chromosome 1 origin. The modal number was
mainly hypertriploid (72, range 69 to 75). Loss of Y was remarkable (0 to 1 copy). Consistent markers
included two copies each of del(1)(q12q31) and der(9)t(1;9)(?;p22), and one der(11)t(4;11) (?;q21). HPV
type 18 genomic integration sites were identified on 1p for PZ-HPV-7 and on the 9p
 
+
 
 marker for CA-
HPV-10. In conclusion, both PZ-HPV-7 and CA-HPV-10 showed clonal cytogenetic changes. These two
cell lines constitute a novel in vitro model to study the mechanisms involved in human prostate car-
cino-genesis. © Elsevier Science Inc., 1997
 
INTRODUCTION
 
During the last decade in Western countries, the apparent
incidence of prostate cancer has shown a tremendous rise
mainly because of improved diagnostic modalities, such
as the tumor marker prostate-specific antigen [1]. In com-
parison, the age adjusted cancer-specific mortality has not
increased significantly, suggesting that prostate cancers
may be diagnosed in the latent stage and that the risk of
over treatment should be considered [2]. Nevertheless,
prostate carcinoma is one of the leading causes of cancer
mortality in the male. Therefore, because of the uncertain
behavior and heterogeneous nature of the disease, the
establishment of methods to distinguish clinically insig-
nificant from potentially lethal cancers has become the
future challenge for prostate cancer research. The develop-
ment of human models for prostate carcinogenesis may
allow for the identification of specific tumorigenic fea-
tures. Even with continuous progress [3], the possibilities
to study primary cells from the human prostate epithelium
are limited by their short lifespan in culture. In search for
an in vitro model of human prostate carcinogenesis, we
used HPV type 18 DNA to immortalize epithelial cell cul-
tures. Two cell lines were established: PZ-HPV-7, an epi-
thelial precursor cell derived from normal prostatic
peripheral zone tissue, and CA-HPV-10, an epithelial pre-
cursor cell derived from a high-grade adenocarcinoma of
the prostate [4].
Characteristic cytogenetic aberrations may shed some
light on tumor specific mechanisms of oncogenesis. Dur-
ing the last decade, several chromosomal abnormalities
have been associated with prostate adenocarcinoma. The
findings of specific karyotypic features of adenocarcinoma
specimens have been significant. Chrosomomal gains and
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losses as well as structural anomalies reported in prostate
cancer include almost all human chromosomes, i.e., 1, 2,
3, 5, 6, 7, 8, 9, 10, 13, 14, 15, 16, 17, 18, 22, X, and Y [5–
18]. Of these chromosomal anomalies some seem to pre-
dominate. Gains of chromosomes X and 7, and 8q may be
involved in prostate cancer progression [11–17] . Among
the most commonly deleted regions implicated in prostate
cancer we find 8p [6–10, 13–17], first suggested in 1988 by
König et al. [19], 10q [5-8, 13, 17], 16q [5, 6, 13, 17], and
also anomalies of the Y chromosome [7, 8, 10, 14–16]. Fur-
thermore, linkage analysis of 91 high-risk prostate cancer
families recently provided strong evidence of a major
prostate cancer supsceptibility locus on chromosome 1
[18]. Interestingly, one of the newly established HPV
transformed cell lines, CA-HPV-10, was derived from a
human prostate cancer cell strain with several karyotypic
abnormalities, including an extra Y chromosome and dou-
ble minutes (dmin) [7].
In this study, we report on the sequential analysis of
both prostate cell lines and a detailed characterization of
CA-HPV-10 marker chromosomes using whole chromo-
some paints and site specific probes. The HPV integration
sites were also investigated using fluorescence in situ hy-
bridization (FISH) methodology.
 
MATERIALS AND METHODS
Cell Lines
 
As reported previously [4], plasmids containing the full
genome of HPV type 18 incubated with lipofectin (BRL
Life Technologies, Gaithersburg, MD) were used for
immortalization of two primary epithelial human prostate
cell strains, LJpz and HSca. The two established cell
lines—PZ-HPV-7, precursor LJpz derived from normal
prostatic peripheral zone epithelium, and CA-HPV-10,
precursor HSca derived from a high-grade (Gleason grade
4
 
1
 
4) prostatic adenocarcinoma specimen—were analyzed
at different passages ranging from early (15 and 14) to late
(99 and 94) numbers. Keratinocyte serum free media
KSFM (GIBCO, Grand Island, NY), added with bovine
pituitary extract (50 ug/ml), epidermal growth factor (5 ng/
ml) and antibiotics was required for optimal growth.
 
Cytogenetics
 
Monolayers of in log phase growing cultures were incu-
bated with colcemid (0.015 
 
m
 
g/ml) for 30 min to one hour.
Longer incubation was required when limited numbers of
rounded or mitotic cells were observed. Subsequently,
metaphase cells were harvested by trypsinization, swollen
in KCl-EGTA (0.075M), fixed in methanol:acetic acid (3:1),
and spread on slides [19]. Chromosomes were identified
by the R-banding and Q-banding technique using acridine-
orange and atebrine, respectively. At least 20 metaphases
from each cell line were karyotyped.
 
Fluorescence in Situ Hybridization (FISH)
 
The DNA probes were labeled with Biotin-16-dUTP by
standard nick translation, precipitated, and resuspended
in hybridization mixture (50% formamide, 10% dextran
sulfate in 2 
 
3
 
 SSCP) with 50 
 
m
 
g salmon sperm DNA and
50 
 
m
 
g yeast t-RNA when competitive hybridization was
necessary. The probe concentration was as follows: 0.5 ng/
 
m
 
l for centromeric probes, 7.5 ng/
 
m
 
l for the HPV probe,
and 10 ng/
 
m
 
l for chromosome-specific libraries. After
probe denaturation (4 min at 72
 
8
 
C), the repeat sequences
were allowed to preanneal with 10 
 
m
 
g Cot-1 DNA for 1 hour
at 37
 
8
 
C. Metaphase spreads on glass were pretreated with
RNAse and 0.2% pepsin (0.01 N HCl), postfixed, and
denatured at 72
 
8
 
C for 2.5 min in 70% formamide. Probes
were hybridized overnight at 37
 
8
 
C in a humidified box.
After washing, the hybridization sites were visualized by
immunochemistry using two layers of FITC in three steps
with avidin-FITC, biotinylated goat-anti-avidin, and avi-
din-FITC. Results were observed in fluorescence using
DAPI banding counterstaining and sometimes cohybrid-
ization with a known probe relevant for chromosome
identification.
 
Probes
 
Various probes were used, single or in combination, in
single or double color experiments.
 
HPV type 18.
 
The full plasmid of HPV type 18 DNA
cloned into pB322 (kindly received from Dr. E-M. de Vil-
liers, Heidelberg, Germany) was used as a probe.
 
Whole chromosome paint.
 
Chromosome specific libraries
pBS 1 to 22, X, and Y, prepared and made available to us
by J. Gray (University of California, San Francisco, USA).
Separate experiments were performed using a commer-
cially available chromosome 11 probe (Cambio LTD) as
well as chromosomes 4 and 9 probes prepared by degener-
ate oligonucleotide-primed-polymerase chain reaction
(DOP-PCR)-amplification [20].
 
Centromere probes.
 
Probe PUC1.77 [21] for chromosome
1, pYAM11-39 [22] for 4, D8Z2 [23] for 8, pHUR98 [24] for
9, pLC11A [25] for 11, pHUR195 [24] for 16, L1.84 [26] for
18, and p3.4 [27] for 20 were used.
 
Gene loci specific probes.
 
Site or gene loci-specific probe
p1.79 (received from H. van Dekken, Rotterdam, The Neth-
erlands) was used for identification of 1p36; oct 7a (received
from R. de Zwart, Rotterdam, The Netherlands) was used
for 1p32/2q23; ERCC3 [28] was used for 2q, 10.62/10.63;
 
p16
 
 tumor suppressor gene [29] was used for 9p21; and
Cos-ABL-18 [30] was used for 9q34.
 
RESULTS
Cytogenetic Analysis
 
The PZ-HPV-7 cell line, precursor originating from a nor-
mal prostatic epithelial cell strain, was studied at passages
15, 38, and 99. PZ-HPV-7 progressed from an initial dip-
loid chromosome number at passage 15 and 38 to a modal
number of 106 chromosome, range 103 to 108. Analysis
showed 3 to 5 copies of all chromosomes except X and Y
(2 copies each) and chromosomes 5 and 20 (7 to 8 copies
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each). There were only a few structural changes: 3p
 
2
 
 (M1,
2 copies), 3q
 
2
 
 (M2, 1 copy), and a third marker possibly a
der(16p;12q)(M3). In Figure 1A the full karyotype is
shown representing the late passage findings as described
above.
The CA-HPV-10 parental cell strain HSca originated
from a core of pure Gleason grade 4 
 
1
 
 4 prostatic adenocar-
cinoma obtained from a radical prostatectomy specimen.
The previously reported karyotype of HSca [7] showed
several abnormalities including an extra Y chromosome
and dmin. At passages 14 and 38, the karyotypes of cell
line CA-HPV-10 varied from hypodiploid to hypotetra-
ploid with a slowly rising mode in the hypertriploid range.
The karyotype was unstable with mainly telomeric associ-
ations, di- and tricentric chromosomes, isochromosomes,
and a decreasing number of cells exhibiting dmin. At pas-
sage 89 the karyotype was mainly hypertriploid (modal
number 72, range 69 to 75) with a few cells hyperhexa-
ploid and hyperdodecaploid. Consistent markers included
two copies each of del(1)(q12q31) (M1) and der(9)t(1;9)(?;p22)
Figure 1 Karyotypes by R-banding of cell lines PZ-HPV-7 at passage 99 (A), and CA-HPV-10 at passage 89 (B). In
(A), small chromosomal markers mainly composed of a centromere are marked as cf. 
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(M2) with probably a large hsr, one der(11)t(4;11)(?;q21)
(M3) and one structurally abnormal der(16)(M4). Chromo-
somes 20 and 5 were overrepresented with an average of 4
and 5 copies, respectively. Loss of Y (0 to 1 copies), as
well as the relative loss of chromosomes 6, 13 (2 to 3 cop-
ies), and 22 (2 copies) was remarkable. ure 1B shows the
full karyotype of the CA-HPV-10 cell line in late passage
as described above.
For identification of CA-HPV-10 markers, detailed FISH
analyses were performed. In initial experiments DOP-PCR-
amplified flow-sorted chromosomes 4 and 9, and a com-
mercially available chromosome 11 probe was used on
metaphase spreads of cell line CA-HPV-10 (passage 89) to
identify the 11q
 
1
 
 and 9p
 
1
 
 markers. These single chromo-
somal paints of chromosomes 4, 9, and 11, as well as cohy-
bridization experiments of 4 and 11 revealed a der(11)t(4;11),
whereas the hsr on 9p was investigated. Subsequently, for
each chromosome, whole libraries were used as paints,
sometimes in combination with specific centromeric probes.
Eight to 31 metaphases were analyzed. Each paint showed
numerical changes consistent with the cytogenetic find-
ings (Table 1) as well as a number of marker chromosomes
(Table 2). The 9p
 
1
 
 hsr is painted with chromosome 1 spe-
cific DNA, which is shown in Figure 2. In double staining
experiments using loci-specific probes for 1p36, 1p32/
2q23, 2q, and 9p21, the hsr was studied in detail. How-
ever, none of these probes were located on the hsr. The
studied probes exhibited an otherwise expected staining
pattern on the respective chromosomes 1 and 2, whereas
the 9p21 probe for the 
 
p16
 
 tumor suppressor gene re-
vealed no deletion.
 
FISH Analysis of HPV 18 Incorporation Sites
 
Preparation of HPV 18 DNA specific probes was estab-
lished using the original purified plasmid. Metaphase
chromosomal spreads of Hela cells, containing several
genomic copies of integrated HPV 18 DNA, were used as
positive controls. At least 20 metaphases of each cell line
were analyzed. Using the full HPV 18 plasmid as a probe,
we obtained a strong hybridization signal in the HeLa cell
line and a weak signal in our cell lines. The weaker signal
was probably because of a low number of copies of the
HPV 18 genome in the PZ-HPV-7 and CA-HPV-10 cell
lines. Both cell lines showed single HPV type 18 genomic
integration sites. For the PZ-HPV-7 cell line, the integra-
tion site was identified on 1p, whereas for the CA-HPV-10
cell line, it was identified on the 9p
 
1
 
 marker. The latter is
 
Table 1
 
FISH analysis of CA-HPV-10 (passage 89) using 
painting probes for chromosomes with 
numerical changes only
 
a
 
Chromosome Number of copies
Y 0 or 1
X, 22 2
6, 13 2 or 3
2, 7, 10, 12, 14, 17, 21 3
15 3 or 4
20 4
5 5
 
a
 
Eight metaphases analyzed per probe.
 
Table 2
 
FISH analysis of CA-HPV-10 (passage 89) using painting probes for chromosomes exhibiting 
numerical and structural changes
 
Probe
Number of 
metaphases
analyzed
Chromosomes (partially) painted
Marker
designation
Chromosome
specific paint
Number of
intact copies Markers
 
a
 
1 9 2 del(1)(q12q31)
 
3
 
2 (M1)
add(9)(p22)
 
3
 
2 (M2)
7 3 del(1)(q12q31) (M1)
add(9)(p22)
 
3
 
2 (M2)
marker (E size)
3 15 3 or 4
7 3 marker (A size)
6 3 marker (D size)
3 2 or 3 marker (G size)
4 8 2 or 3 der(11)t(4;11)(?;q21) (M3)
8 7 3
3 2 or 3 der(16) (M4)
9 8 2 add(9)(p22)
 
3
 
2 (M2)
11 5 3
16 2 or 3 der(11)t(4;11)(?;q21) (M3)
16 4 3
4 2 der(16) (M4)
18 3 3
5 3 small marker
19 4 2 or 3
4 2 or 3 small marker
 
a
 
Markers are described by their appearance, DAPI banding and (partial) paint. (M1–4), markers indicated in karyotype (Fig. 1B).
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demonstrated in Figure 3 in a double staining experiment
with the centromere 8 probe.
 
DISCUSSION
 
As a model for the study of prostate carcinogenesis, two
epithelial cell lines, PZ-HPV-7 and CA-HPV-10, have been
established using HPV type 18 DNA. Immortalization with
the HPV type 18 genome was attempted because HPV
DNA sequences have been detected in human prostatic tis-
sues of different histologies [31–36], and the detected HPV
DNAs were shown to be transcriptionally active [37],
although the role of HPV in the prostate remains unclear
[38]. Another reason to perform HPV transformation stud-
ies was to prolong the limited in vitro lifespan of human
epithelial prostate cells per se, which had been accom-
plished previously using SV40 DNA [39–41]. The result-
ing cytogenetic changes were evaluated in the described
analysis. The PZ-HPV-7 cell line, originating from a nor-
mal epithelial human prostate cell strain, was diploid and
relatively unchanged at early (15 and 36) passage. PZ-
HPV-7 progressed in culture to a modal number of 106
chromosomes with mostly numeric changes and only a
few structural markers. In contrast, CA-HPV-10 showed a
hypertriploid mode in both analyses of early and late pas-
sages, with a number of characteristic markers, which
were not fully present in the earlier passages. Loss of chro-
mosome 22 was of interest, because it was not observed in
HPV immortalized keratinocyte cell lines [42] nor in HPV
immortalized cell lines from other organ systems [39–42].
Furthermore, the relative gain of both chromosomes 5 and
20 in the two cell lines, PZ-HPV-7 and CA-HPV-10, was
remarkable. This combination has not specifically been
described before as an HPV transformation related phe-
nomenon, although a gain of chromosome 20 has been
reported [43–45].
After HPV transfection triploidization is rather com-
monly described as well as structural genomic rearrange-
ments [45, 46]. Also, single site HPV DNA integration was
observed in cervical carcinoma cell lines [47]. HPV se-
quences of cervical carcinoma cell lines integrated on nor-
mal and abnormal chromosomes. The staining pattern of
HPV 16 integration sites showed evidence of replication
together with the heterochromatic regions of chromosomes
1, 9, and 16 [48]. Reznikoff et al. [44] showed how the ini-
tial genetic alterations may direct late genetic changes and
Figure 2 CA-HPV-10 cell line metaphase spread using DAPI counterstaining (left side) for chromosome identifi-
cation and whole chromosome paints (right side) for 1 (staining red) and 9 (staining green). Two copies of the 9p1
hsr are stained with chromosome 1 specific DNA (arrowhead). Three copies of 1 are indicated with an asterix.
Figure 3 The HPV type 18 DNA integration site (green) of the
CA-HPV-10 cell line is shown on 9p1 (arrowhead). In this exper-
iment double staining with a centromere 8 probe was used to dis-
tinguish C sized chromosomes 8 and 9.
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how different combinations of genetic alterations work to-
gether to block cellular senescence, initiate tumorigenesis,
and lead to tumor progression in transitional cell carcinoma.
After transfection of HPV type 16 E6, which represents one
of the early gene regions involved in transformation, a spe-
cific association of 3p loss with chromosome 9 instability
was found. These karyotypic changes would seem to fit
the general cytogenetic features of the PZ-HPV-7 and CA-
HPV-10 cell lines. 
Loss of the Y chromosome is of interest in view of re-
cent studies. Gains as well as deletions of the Y chromo-
some were found in prostatic carcinomas using in situ
hybridization [10, 14–16]. Recently, loss of the Y-chromo-
some was found in metastatic prostate carcinoma speci-
men, whereas the primary carcinoma and adjacent
prostatic intraepithelial neoplasia lesions did not show
this deletion [15]. However, it is unclear whether this loss
of the Y-chromosome is a relatively nonspecific or possi-
bly significant cytogenetic correlate of progression in pros-
tate cancer. It has been found in other urinary tract tumors
[49, 50]. Our findings could be significant although cyto-
genetic phenomena associated with the HPV immortaliza-
tion should be considered. Relative marked loss of the Y
chromosome was found in the cell line CA-HPV-10, which
was derived from a high-grade adenocarcinoma precursor
cell strain HSca, that had an extra Y chromosome before
transfection [7]. The PZ-HPV-7 cell line did not show such
a prominent loss of the chromosome.
In addition to an abnormal karyotype of 47,XY,
 
1
 
Y, the
precursor cell strain of CA-HPV-10 contained dmin chro-
mosomes. The presence of both dmin and hsr is suggestive
of gene amplification events possibly representing onco-
gene amplification [51], as has been reported in other solid
tumors [52, 53]. The cytogenetic evaluation with banding
techniques of cell line CA-HPV-10 showed an hsr on chro-
mosome 9p. Instead of a possible complex translocation,
additional painting experiments revealed the configura-
tion of a translocation, der(11)t(4;11)(?;q21r). The hsr on 9p
was studied using whole chromosome paints, which
showed its chromosome 1 origin. The determination of
HPV integration sites on 1p in the PZ-HPV-7 cell line and
9p
 
1
 
 in chromatin of 1 on the add(9)(p22) in the CA-HPV-
10 cell line does raise the question of whether there is a
preferential integration site following HPV transfection in
prostate epithelial cells. Using several loci specific probes,
the 9p
 
1
 
 marker was targeted; however, because none were
found to be located on the hsr, the conclusions from these
experiments were limited. A probe for the 
 
p16
 
 tumor sup-
pressor gene located on 9p21 [29] showed no deletion.
The question of whether the hsr and dmin were retained
in CA-HPV-10 or if they resulted from the HPV immortal-
ization remains open. The formation of hsr as a reflection
of DNA amplification has been described after HPV im-
mortalization of keratinocytes [48]. Unfortunately, the
original metaphase spreads of the CA-HPV-10 precursor
HSca were not available for additional chromosomal
painting, but it would seem appropriate to assume that the
dmin and hsr of the CA-HPV-10 cell line have been re-
tained from the precursor cell. Efforts to isolate these par-
ticular hsr and dmin using flow sorting techniques [20]
have been unsuccessful because of the high viscosity of
chromosome suspensions from these cells. Nevertheless,
further studies for isolation of these aberrant chromosomal
parts are warranted, because building a physical map of
the involved regions could provide new insights of mecha-
nisms involved in human prostate carcinogenesis.
The cytogenetic evaluation of PZ-HPV-7 and CA-HPV-
10 revealed several karyotypic abnormalities that can be of
interest in the pursuit of a multistep in vitro model of hu-
man prostate carcinogenesis. The cytogenetic modifica-
tions that were identified represent a range of HPV
transfection related phenomena within the residual pat-
tern of the original karyotype.
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